Feed AMGN
AM

Amgen

AMGN · NASDAQ

$414.61 +1.56% (+$6.36)
1M -4.12%
Market Cap $212.2B
P/E Ratio 24.27x
Div. Yield 2.53%
ROE 89.32%

Bulios Fair Price

$429.7

3.6% upside

Trenutna cena

$414.61

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price se delnica AMGN trenutno trguje blizu svoje poštene vrednosti. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Strong
8/9
Valuation
49 /100
Fair
P/E 24.27x
P/FCF 20.85x
EV/EBITDA 15.48x
Growth
53 /100
Stable
EPS growth 5.52%
Book val. growth 33.23%
Rev. growth 11.76%
Profitability
100 /100
Strong
Gross margin 72.65%
FCF margin 26.69%
Net margin 22.93%
Quality
78 /100
Excellent
ROIC 14.22%
Asset turnover 0.40x
ROE 89.32%
Debt
37 /100
Moderate
Debt/Equity 4.90x
Net debt/EBITDA 2.62x
Current ratio 1.37x
Stability
65 /100
Moderate
Beta 0.43x
Profitable years 6
Rev. volatility 5.98%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o AMGN
Online

O podjetju

Amgen Inc. is an American biotechnology company specializing in research, development, and manufacturing of biologic medicines. The company focuses on innovative therapeutic treatments for various diseases, including cancer, cardiovascular conditions, arthritis, and other serious illnesses. Amgen has developed a range of successful drugs that have transformed the lives of patients worldwide. The company also invests in research for new drugs and treatment approaches to better address current and future healthcare challenges. Amgen collaborates with physicians, scientists, and other experts to improve healthcare and develop new therapeutic options. Amgen Inc. (AMGN) shares are an interesting choice for investors who follow the biotechnology sector and seek investment opportunities in a reputable company that brings innovative therapeutic treatments for serious diseases.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Robert A. Bradway

Employees

31,500

Headquarters

Thousand Oaks

Prihajajoči dogodki

03 NOV.

Earnings

Upcoming earnings report

37d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.